Noxopharm Limited
Noxopharm Limited (NOXOF) Revenue
Annual & quarterly revenue history · segment & region breakdown
NOXOF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsNoxopharm Limited trailing twelve-month (TTM) revenue is $0.01B, a decrease of 60.06% year-over-year from $0.00B in FY2024.
Revenue trend
2024 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-06-30 | $0.00B | -$0.00B | -60.06% |
| 2023-06-30 | $0.01B | +$0.00B | +10.71% |
| 2022-06-30 | $0.01B | -$0.00B | -3.20% |
| 2021-06-30 | $0.01B | -$0.00B | -32.29% |
| 2020-06-30 | $0.01B | +$0.00B | +120.82% |
| 2019-06-30 | $0.00B | +$0.00B | +309.22% |
| 2018-06-30 | $0.00B | +$0.00B | +625.69% |
| 2017-06-30 | $0.00B | +$0.00B | — |
| 2016-03-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Noxopharm Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Noxopharm Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in AUD.
Data sourced from Noxopharm Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NOXOF revenue · 4 questionsNOXOF's trailing twelve-month (TTM) revenue is $0.01B. That is a decrease of 60.06% year-over-year from $0.00B in FY2024.
▸ Source: FMP · Noxopharm Limited SEC filings · GAAP · Noxopharm Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026